A phase II, 52 week study assessing ALT-801 for Non-alcoholic steatohepatitis
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Pemvidutide (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Altimmune
- 28 Sep 2021 According to an Altimmune media release, the company expect to initiate this trial in H1 2022.
- 16 Jun 2021 According to an Altimmune media release, the company expect to initiate this trial in Q1 2022.
- 17 May 2021 According to an Altimmune media release, the company anticipate filling IND in mid-year to initiate U.S. NASH studies.